FDA rejection of Spero’s tebipenem ‘raises resistance threat’
The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of […]
The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of […]
Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down […]
Entasis Therapeutics is being acquired by Innoviva in a deal that brings an FDA-ready antibiotic developed to address drug-resistant strains of a bacterium that infects […]
A study has found that there is still a very high level of inappropriate antibiotic prescribing to patients in the US, particularly to older and […]
The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of […]
Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which is focusing on the use of artificial […]
Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in […]
AN2 is developing an antibiotic based on boron chemistry that could offer advantages over carbon-based molecules. The biotech plans to advance its drug candidate, licensed […]
Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed […]
Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million […]
Copyright © 2024 | WordPress Theme by MH Themes